Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
nkt5097 cdk2/cdk4 dual degrader
Hormone Receptor-Positive Breast Cancer
NiKang Therapeutics, Inc.
P1
CC
(43)
nkt5097 cdk2/cdk4 dual degrader
Triple-Negative Breast Carcinoma
NiKang Therapeutics, Inc.
P1
CC
(43)
nkx019
Aggressive B-Cell Non-Hodgkin Lymphoma
Nkarta, Inc.
P1
CC
(43)
nkx019
B-Cell Acute Lymphoblastic Leukemia
Nkarta, Inc.
P1
CC
(43)
nkx019
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nkarta, Inc.
P1
CC
(43)
nkx019
Large B-Cell Lymphoma
Nkarta, Inc.
P1
CC
(43)
nkx019
Anaplastic Large Cell Lymphoma
Nkarta, Inc.
P1
CC
(43)
nkx019
Non-Hodgkin Lymphoma
Nkarta, Inc.
P1
CC
(43)
nkx019
Mantle Cell Lymphoma
Nkarta, Inc.
P1
CC
(43)
nkx019
Waldenstrom Macroglobulinemia
Nkarta, Inc.
P1
CC
(43)
nkx101 - car nk cell therapy
Acute Myeloid Leukemia
Nkarta, Inc.
P1
CC
(43)
Nlg 802
Cancer
Luke, Jason, MD
P1
CC
(43)
nm32-2668
Lung Adenocarcinoma
Numab Therapeutics AG
P1
CC
(43)
nm32-2668
Gastric Adenocarcinoma
Numab Therapeutics AG
P1
CC
(43)
nm32-2668
Liposarcoma
Numab Therapeutics AG
P1
CC
(43)
nm32-2668
Peritoneal Carcinoma
Numab Therapeutics AG
P1
CC
(43)
Nms-03597812
Acute Myeloid Leukemia
Nerviano Medical Sciences
P1
CC
(43)
nn3201
Adenoid Cystic Carcinoma
Novelty Nobility, Inc.
P1
CC
(43)
nn3201
Chromophobe Renal Cell Carcinoma
Novelty Nobility, Inc.
P1
CC
(43)
nn3201
Gastrointestinal Stromal Tumor
Novelty Nobility, Inc.
P1
CC
(43)
nn3201
Neuroendocrine Neoplasm
Novelty Nobility, Inc.
P1
CC
(43)
nn3201
Small Cell Lung Carcinoma
Novelty Nobility, Inc.
P1
CC
(43)
nn3201
Uveal Melanoma
Novelty Nobility, Inc.
P1
CC
(43)
nnc4005-001
Fatty Liver Disease
Novo Nordisk A/S
P1
CC
(43)
Nogitecan
Pancreatic Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Showing 3526 to 3550 of 9,920 assets
Previous
Page 142 of 397
Next
